247 results about "Fibronectin" patented technology

The invention belongs to the technical field of recombinant protein, and particularly relates to recombinant human fibronectin as well as an expression method and application thereof. The recombinant human fibronectin provided by the invention selects a fibronectin core functional domain III9-10 / III12-14, the core functional domain III9-10 / III12-14 is modified and transformed to obtain an encoding gene, and the encoding gene is transferred into escherichia coli and expressed to obtain the recombinant human fibronectin. The obtained recombinant human fibronectin has good stability, proliferation promoting activity and cell migration promoting capacity, can be applied to skin care products or cosmetics, and has important use value and practical significance.

The invention discloses a spirulina platense skin extract as well as a preparation method and application thereof, and relates to the technical field of biomedicine. The obscured spirulina skin extract is rich in various active ingredients including collagen family members, viscose protein, C1Q complement protein, fibronectin and the like, and the ingredients complement and promote one another, so that the extract has remarkable effects in the aspects of skin aging resistance, skin injury repair and the like; therefore, the method has a wide application prospect in medicine research and development, cosmetics and functional foods. According to the extraction method of the skin protein of the obtuse spirulina, the sample is subjected to rapid freeze thawing treatment, and the steps of mechanical crushing, ultrasonic-assisted separation and multiple filtration are combined, so that the influence on the activity of the product is avoided, and various compound proteins can be obtained; the pH value of a buffer solution is adjusted, the property of the extract is further optimized, and the extract is more suitable for human skin, is sterile and can be directly used as a product raw material, so that large-scale production is realized, and industrial application of the obtuse spirulina skin extract is promoted.

The invention belongs to the technical field of cosmetics, and discloses a wrinkle-removing and anti-aging composition containing recombinant collagen as well as a preparation method and application of the wrinkle-removing and anti-aging composition. The composition is prepared from the following components: 20.4 to 35.6 percent of glycerol, 1.1 to 3.5 percent of 1, 2-hexanediol, 8.2 to 15.4 percent of apple fruit cell culture extract, 1.6 to 3.2 percent of inositol, 0.2 to 1.0 percent of elastin, 0.1 to 1.7 percent of hydroxyproline, 0.1 to 1.0 percent of sodium polyglutamate, 0.1 to 1.0 percent of sodium hyaluronate, 0.01 to 0.1 percent of acetyl hexapeptide-8, 0.01 to 0.1 percent of fibronectin, 1.72 to 3.21 percent of soluble collagen and the balance of deionized water. The amino acid sequence of the soluble collagen is as shown in SEQ ID NO. 1. The skin care product prepared by adding the anti-wrinkle and anti-aging composition is good in safety and has the effects of resisting wrinkles, improving skin elasticity and resisting aging.

The invention provides an instant red-removing composition and application thereof, a cosmetic composition and a preparation method thereof, and relates to the technical field of cosmetics. The instant redness-removing composition comprises the magnolin and the fibronectin, and compared with single use of the magnolin or compound use of the magnolin and the redness-removing agent, the instant redness-removing composition comprising the magnolin and the fibronectin is high in safety and can quickly relieve and eliminate the phenomenon that the skin becomes red. The cosmetic composition capable of instantly removing redness is high in stability, can solve the problem and demand of instantly removing redness on different skins, is simple and convenient in preparation method and high in operability, and has a wide market prospect.

The invention discloses a method for simulating a tumor blood vessel growth process. The method comprises the following steps: constructing a two-dimensional discrete coordinate system based on a tumor two-dimensional model, and defining a blood vessel index function for describing unit grid attributes of unit grids; updating the cell number, the oxygen concentration, the fibronectin concentration and the growth factor concentration of each unit grid every preset time t; predicting the movement direction of the blood vessel tip in the t time period according to the fibronectin concentration and the growth factor concentration; calculating a first predicted extension distance and a second predicted extension distance according to the motion direction in the current t time period and the motion direction in the last t time period; and updating the unit grid attribute of each unit grid in the two-dimensional discrete coordinate system according to the movement direction in the t time period, the blood vessel existence time of the blood vessel tip and the movement extension distance calculated by the blood vessel tip. The oxygen concentration and the number of cells are incorporated into the tumor blood vessel growth model, and accurate simulation prediction of the tumor blood vessel growth process is achieved.

The invention relates to a plasma biomarker for predicting the curative effect of non-small cell lung cancer immunotherapy and application of the plasma biomarker. The biomarker for predicting the curative effect of the non-small cell lung cancer immunotherapy, disclosed by the invention, comprises phosphoglycerate kinase 1 (PGK1), fibronectin 1 (FN1), chromogranin A (CHGA), elastin (ELN), heterogeneous ribonucleoprotein H3 (HNRNPH3) and an Aly / REF output factor (ALYREF). The plasma biomarkers for predicting the non-small cell lung cancer immunotherapy curative effect can be detected by adopting a mass spectrum method, and the non-small cell lung cancer immunotherapy curative effect of a patient is judged by the markers.

The invention provides a probe for cell senescence analysis and a preparation method and application thereof, and belongs to the technical field of cell detection. The invention discloses a probe for cell aging analysis. The probe comprises fusion protein formed by fibronectin RGD and fluorescent protein, the fibronectin RGD is a polypeptide fragment containing an amino acid sequence as shown in SEQ ID NO: 1. The probe is fixed on a solid-phase carrier and then co-incubated with cells to be detected, the condition of senescent cells can be analyzed and judged by detecting the intensity of a fluorescence signal, the purpose of rapid analysis is achieved, the analyzed cells can be recycled and then continuously cultured, the detection cost is low, and the probe is suitable for large-scale popularization and application in the market.

The present invention relates to the fields of medicine and cosmetology, and discloses a cell active peptide composition that promotes the regeneration of multi-type collagen structural proteins, its preparation method, and its application in medicine and cosmetology. The composition uses raw materials such as tripeptide-10 citrulline, hexapeptide-9, hydrolyzed sodium hyaluronate, γ-aminobutyric acid, decarboxylated carnosine hydrochloride, acetyl tetrapeptide-3, acetyl tetrapeptide-11, palmitoyl dipeptide-7, and palmitoyl pentapeptide-4. The composition can promote the coordinated expression of skin type I, type III, type IV, type VII, type XVII collagen, fibronectin, elastin, and glycosaminoglycans; prevent collagen cross-linking, maintain triple helix structure, and inhibit collagen degradation. Applied to dermatology and cosmetology, it can accelerate the regeneration of structural proteins such as skin collagen, repair skin damage, reduce wrinkles such as crow's feet, tear groove lines, nasolabial folds, and under-eye lines, solve the skin aging problem caused by the loss of structural proteins such as collagen, and improve skin elasticity and firmness.

The invention discloses an rhFN recombinant human chemical fibronectin process of a genetic engineering technology, and particularly relates to the technical field of genetic engineering, and the rhFN recombinant human chemical fibronectin process comprises target gene acquisition, gene cloning and vector construction, host cell selection and transformation, cell culture and screening, protein expression and optimization, and protein separation and purification. According to the rhFN recombinant human chemical fibronectin process of the genetic engineering technology provided by the invention, high-quality target genes are accurately obtained through technologies such as new-generation sequencing and gene synthesis, and the gene expression efficiency and stability are enhanced by virtue of optimized vector construction and regulatory elements; protein expression ability and specificity are improved in host cell selection and transformation, efficient culture and accurate screening are realized in cell culture and screening links, total yield is increased in a protein expression optimization link, purity and efficiency are improved in a protein separation and purification link, and product quality and safety are ensured through comprehensive quality control. The requirements in the fields of medical treatment and scientific research are expected to be better met.

Provided are antibodies that include amino acid sequences of SEQ ID NOs: 2, 4, and 6-12, or amino acid sequences that are about 95% identical thereto, and fragments thereof. Also provided are scFv peptides that include a VH segment having a first amino acid sequence of amino acids 4-113 of any one of SEQ ID NOs: 2 and 8-12, a VL segment having a second amino acid sequence having amino acids 113-237 of SEQ ID NOs. 2 and 8-12, or both; nucleic acids encoding the same; methods for using the same to detect and / or target conformational states of FN in samples; methods for treating diseases and / or disorders and / or for meliorating at least one symptom of consequence of a disease or disorder associated with abnormal expression of a force-induced conformational state of FN in subjects; and methods for screening for compounds having selective binding activities for conformational states of FN.

The invention discloses recombinant human chemical fibronectin as well as a coding gene and application thereof. The method comprises the following steps: performing codon optimization on an amino acid sequence of recombinant human chemical fibronectin according to codon preference of pichia pastoris to obtain a coding gene nucleotide sequence SEQ ID NO.2, cloning the coding gene nucleotide sequence SEQ ID NO.2 between EcoRI and NotI restriction enzyme cutting sites of a pichia pastoris expression vector pPIC9K to obtain a recombinant expression vector pPIC9K-FNc, and transferring the recombinant expression vector pPIC9K-FNc into a P.pastoris GS115 expression host cell to obtain the recombinant human chemical fibronectin. Recombinant pichia pastoris P.pastoris GS115 / pPIC9K-FNc is obtained through genetic mycin G418 screening, then recombinant bacteria are subjected to fermentation culture and are subjected to induced expression by using methanol, and then the recombinant human chemical fibronectin is obtained after purification. The fibronectin produced by the method is large in molecular weight and has better biological activities such as wrinkle resistance and barrier repair.

The invention relates to the technical field of collagen dressings, in particular to a moisturizing and repairing collagen dressing and a preparation method thereof. The moisturizing and repairing collagen dressing is prepared from the following components in parts by mass: 10 to 30 parts of recombinant human fibronectin, 10 to 20 parts of recombinant collagen, 5 to 15 parts of beta-glucan, 5 to 10 parts of compound hexanediol, 40 to 50 parts of carbomer, 5 to 15 parts of a flavoring agent, 80 to 120 parts of purified water, 10 to 30 parts of a modified recombinant human III type collagen solution and 10 to 20 parts of a modified chitosan solution. The recombinant human fibronectin disclosed by the invention can be deposited at an injured part to form a blood clot, so that the aim of stopping bleeding is fulfilled, and the subcutaneous tissue is protected; the recombinant collagen has high biological activity and can inhibit inflammation and improve the conditions of pachulosis, damage and the like of the skin; the beta-glucan can generate cytokines, promote healing of skin with laser-dependent dermatitis or barrier damage, and realize anti-allergic and anti-inflammatory effects.

The invention relates to the technical field of biology, and particularly discloses a construction method and application of an endometrial epithelium organ fibrosis model. According to the method, human endometrial epithelial cells are extracted, and an endometrial epithelial organ is established by adopting a Matrigel three-dimensional culture system. Afterwards, the organoid is induced to form endometrial phenotypes in different physiological cycles through hormone stimulation, and a ferroptosis inducer FIN56 is added in the culture process to induce fibrosis. The expression of GPX4, Fibronectin and p-Smad2 / 3 is detected through Western blot and immunofluorescence, and the successful construction of the fibrosis model is verified. The invention provides an in-vitro model capable of simulating endometrial fibrosis pathological characteristics of a patient with PCOS (polycystic ovarian syndrome), the in-vitro model can be used for mechanism research and drug screening of PCOS-related endometrial lesions, and a new research tool and an intervention strategy are provided for treatment of PCOS endometrial fibrosis.

Compositions and methods diagnose and / or treat chronic kidney disease (CKD) using one or more feline circulating proteins as markers for early-stage CKD. A method of diagnosing chronic kidney disease (CKD) in a feline can include measuring an amount of each of at least one circulating protein from the feline. The at least one circulating protein is one or more of adiponectin (ADIPOQ), cathelicidin (CAMP), kinesin-like protein (KIF12), plasma retinol-binding protein (RBP4), Ig-like domain-containing protein (ZKSCAN1), coagulation factor X (F10), fibronectin (FN1) and mixtures thereof. The method also includes performing comparison of the amount of each of the at least one circulating protein from the feline to a corresponding predetermined value or a corresponding predetermined range. The method also includes diagnosing the feline as having early-stage CKD or not having early-stage CKD, based on the comparison.

The invention discloses a diabetic retinopathy process simulation method. The method comprises the steps that a two-dimensional discrete coordinate system is constructed, and a blood vessel index function describing unit grid attributes of unit grids is defined; updating the blood glucose concentration, the oxygen concentration, the fibronectin concentration and the growth factor concentration of each unit grid every preset time t; predicting the movement direction of each blood vessel tip in the t time period according to the fibronectin concentration and the growth factor concentration; calculating a first predicted extension distance and a second predicted extension distance according to the motion direction in the current t time period and the motion direction in the last t time period; and updating the unit grid attribute of each unit grid in the two-dimensional discrete coordinate system according to the movement direction in the t time period, the blood vessel existence time of the blood vessel tip and the movement extension distance calculated by the blood vessel tip. According to the method, the oxygen concentration and the blood glucose concentration are incorporated into the model for simulating vascular extension, and accurate simulation prediction of diabetic retinopathy is achieved.

The invention provides a liquid crystal bionic water-locking and oxygen-permeating nursing composition as well as a preparation method and application thereof, and belongs to the technical field of cosmetics. The skin care product is prepared from components in percentage by weight as follows: 20%-40% of glycerin, 5%-10% of hydrogenated lecithin, 5%-10% of phytosterols, 0.1%-0.5% of sodium stearoyl glutamate, 0.01%-0.05% of sodium methyl stearoyl taurate, 0.1%-1% of ceramide NP, 1%-10% of caprylic / capric triglyceride, 1%-10% of squalane, 0.1%-1% of tocopheryl acetate, 0.01%-0.3% of DNA sodium, 0.001%-0.1% of fibronectin and the balance of water. 0.001-0.1% of soluble collagen and the balance of water. The liquid crystal bionic water-locking and oxygen-permeating nursing composition provided by the invention can better form a breathable protective film on the surface of skin, reduce water loss of the skin and help to repair a damaged skin barrier, so that the water-locking and oxygen-permeating nursing effect is achieved.

The invention discloses a lung airway organoid culture system with a trachea branch morphological structure as well as application and a culture method of the lung airway organoid culture system, and relates to the technical field of lung airway organoid culture. The hydrogel culture system is prepared from I-type rat tail collagen, gelatin, hyaluronic acid, laminin, low-melting agarose, chondroitin sulfate, fibronectin, elastin, epidermal growth factors, fibronectin L and transglutaminase; the induction culture medium is prepared from a 1XB27 supplement, a fiber growth factor, glutamine, glutathione, A8301, SB202190, IBMX, 8-Br-cAMP, FGF7, FGF10, Shh and ascorbic acid. The culture system is clear in component, low in price and cost and simple and convenient in preparation method, more importantly, the lung airway organoid which is closer to the physiological state can be efficiently induced to be formed within a short time, and the generated organoid has a branch form similar to an in-vivo trachea and contains various types of functional airway epithelial cells at the same time; and a more preferable scheme is provided for constructing an airway organ with an airway branch form based on the adult lung stem cells.

The invention discloses a recombinant human fibronectin peptide as well as a preparation method and application thereof, and relates to the field of protein. The recombinant human fibronectin peptide disclosed by the invention can promote cell adhesion, proliferation or migration, and has a wide application prospect in the fields of cosmetics and medical instruments. The invention further discloses a method for producing the recombinant human fibronectin peptide through genetic engineering and fermentation engineering, and a foundation is laid for large-scale industrial production.

The invention relates to the technical field of biological medicine, in particular to I-type humanized collagen as well as a preparation method and application thereof. The amino acid sequence of the type I humanized collagen prepared by the invention is shown as a sequence SEQ ID NO. 1 (HTGAWGKTVIEYKTTKTSRLVMGFXGPKGAA, wherein X is hydroxyproline). The invention also discloses a preparation method of the type I humanized collagen. The I-type humanized collagen contains essential amino acids and semi-essential amino acids of a human body, promotes proliferation of human skin fibroblasts, up-regulates expression of elastin, fibronectin and collagen I genes, and has the effects of interacting with endothelial cells and osteoblasts, promoting creeping and growth of the osteoblasts, and promoting the growth of the osteoblasts. And the interaction between osteoblasts and collagen is promoted. Therefore, the I-type humanized collagen can be widely applied to orthopedic sports materials and has application prospects in the fields of medical cosmetology and sports medicine materials.

The invention belongs to the technical field of medicines, and particularly relates to application of sophora alcohol T in preparation of an anti-hepatic fibrosis medicine. The invention provides the application of the sophora alcohol T in preparation of the anti-hepatic fibrosis medicine for the first time, for example, the sophora alcohol T can be applied to preparation of the medicine for preventing or treating hepatic fibrosis. The compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise, and has good patent medicine potential and wide development, transformation and clinical application value and prospect, and the compound can be used for preparing medicines for inhibiting hepatic stellate cell proliferation or activation, inhibiting fibronectin level rise, inhibiting alpha-smooth muscle actin level rise or inhibiting I-type collagen level rise.

The present invention discloses an axolotl skin extract, its preparation method and applications, relating to the technical field of biomedicine. The axolotl skin extract is rich in various active ingredients, including members of the collagen family, fibronectin, C1Q complement protein, fibronectin, etc. These ingredients complement and promote each other, making the extract have remarkable effects in aspects such as skin anti-aging and skin injury repair, and thus having broad application prospects in drug R & D, cosmetics and functional foods. The method for extracting axolotl skin protein, through rapid freeze-thaw treatment of samples, combined with mechanical crushing, ultrasonic-assisted separation and multiple filtration steps, avoids the influence on the activity of the product, and can obtain a variety of composite proteins; adjusting the pH value of the buffer solution further optimizes the properties of the extract, making it more suitable for human skin, and being sterile and directly usable as the raw material of the product, realizing large-scale production and promoting the industrial application of axolotl skin extract.

The present invention discloses a method for simulating the tumor blood vessel growth process, comprising constructing a two-dimensional discrete coordinate system based on a two-dimensional tumor model and defining a blood vessel index function that describes the cell grid properties of the cell grid; updating the cell number, oxygen concentration, fibronectin concentration, and growth factor concentration of each cell grid at preset intervals t; predicting the movement direction of the blood vessel tip within the current time period t based on the fibronectin concentration and growth factor concentration; calculating a first predicted extension distance and a second predicted extension distance based on the movement direction within the current time period t and the movement direction within the previous time period t; and updating the cell grid properties of each cell grid in the two-dimensional discrete coordinate system based on the movement direction within the current time period t, the vessel tip's existence time, and the movement extension distance calculated from the vessel tip. The present invention incorporates oxygen concentration and cell number into the tumor blood vessel growth model to achieve accurate simulation and prediction of the tumor blood vessel growth process.

The invention belongs to the technical field of medicines, and particularly discloses application of fibronectin 1 (FN1) in treatment of mycobacterial infection. The invention finds that the FN1 has new application, and the survival of mycobacteria can be inhibited when the FN1 is independently applied; in a mycobacterium infection model, after the FN1 protein is exogenously added, the number of mycobacteria in macrophages is remarkably reduced; on the contrary, after the FN1 is knocked down, the number of mycobacteria in the macrophage is obviously increased. Further mechanism research shows that the FN1 affects release of reactive oxygen species (ROS) and cytokines by regulating a PI3K / AKT signaling pathway, and further removes mycobacteria in macrophages. From the perspective of host immunity, the invention discloses a mechanism that FN1 affects ROS (reactive oxygen species) and inflammatory response by regulating a PI3K / AKT signal channel so as to inhibit mycobacteria, and a new medicine is provided for treatment of mycobacteria infection. On the basis, FN1 can be independently used or combined with first-line antituberculosis drugs, and a new means is provided for solving the problem of drug resistance in mycobacterium infection treatment.

The invention discloses a construction method of an endothelial progenitor cell model for pulmonary arterial hypertension research, which comprises the following steps: (1) enriching and separating mononuclear cells centrally existing in CD34 cells in peripheral blood of a pulmonary arterial hypertension patient by adopting Histopaqui-10771, then culturing and resuspending the mononuclear cells in an EGM-2MV culture medium containing growth factors, then spreading in a culture plate coated with fibronectin for culturing; (2) 2 days after planking, sucking away non-adherent cells; and cleaning the adherent cells, adding the EGM-2MV culture medium containing the growth factors again for continuous culture, changing the culture medium and adding fibronectin at regular time during culture, inducing directional differentiation of the endothelial progenitor cells, and culturing for 2 weeks to start to appear the endothelial cells. The injury state of the endothelial cells in the disease is represented by the endothelial cells differentiated from the endothelial progenitor cells of the pulmonary hypertension patient, the research on the pulmonary hypertension cells and molecular mechanisms is facilitated, and the method is used for screening pulmonary hypertension treatment drugs and exploring potential pulmonary hypertension treatment targets.

Provided herein are methods for improving glycemic control in a human patient, methods for treating, preventing or reducing overweight or obesity and related co-conditions, and methods for treating or preventing type II diabetes mellitus by administering a polypeptide to the patient, the polypeptide comprises a fibronectin type III tenth (10Fn3) domain that binds to a myostatin. In some embodiments, the polypeptides are administered according to a specific clinical dosing regimen (e.g., at a specific dose and according to a specific time interval) (or for administration according to the regimen).

A method for the expression and / or for the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin. the method comprises applying to human skin at least one caviar extract which is capable of causing the expression and / or the amplification of the expression of thrombospondin-1, fibronectin, vimentin and / or mimecan in human skin.

The invention belongs to the technical field of biology, and particularly relates to a preparation method and application of tumor infiltrating lymphocytes. Keratinase modified by myristoyl coenzyme A cooperates with fibronectin and elastase, so that tumor cells quickly fall off from tumor blocks, and loose tissues are subjected to low-temperature enzymolysis by protease-K, so that the phenotype and activity of tumor infiltrating lymphocytes can be protected; an eicosapentaenoic acid solution is mixed with polysorbate, ultrapure water and a culture medium matrix to obtain an emulsion mixed solution, the emulsion mixed solution is subjected to rotary evaporation to remove a solvent, and the amplification-promoting nanoparticles obtained after freeze drying can make tumor infiltrating lymphocytes ingest effective components more quickly; the tumor infiltrating lymphocytes extracted by the invention are high in activity and rapid in proliferation and growth, still have high cell activity after cryopreservation, and have good anti-breast tumor activity.

A treated human umbilical cord composition for use in the treatment of Perony's disease by in vivo injection in a subject in need thereof using an effective amount of the composition. The composition comprises a water-based human umbilical cord filtrate, wherein endogenous hyaluronic acid (HA) and / or hyaluronic acid, fibronectin, insulin growth factor binding protein-1 (IGFBP-1), sulfated glycosaminoglycan (sGAG), exosomes, interleukin-1 receptor antagonist (IL-1ra), hepatocyte growth factor (HGF), transthyretin, metalloproteinase tissue inhibitor 1 (TIMP-1), and / or a pharmaceutically acceptable salt thereof in an amount effective to reduce the size of Pteroid disease plaques. The present invention relates to an aggregation glycan, or a combination thereof.

The invention discloses application of a small molecule compound Z1149421873 in preparation of a medicine for preventing and treating myocardial fibrosis. On one hand, the small molecule compound Z1149421873 delays the myocardial fibrosis process through targeted inhibition of a myocardial fibrosis target NAP1L1 protein, and protects the cardiac function; on the other hand, the compound has the effect of inhibiting the myocardial fibrosis process and recovering the cardiac function, and the small molecule compound Z1149421873 in a fibroblast activation model inhibits the transcription and translation levels of I-type collagen, alpha-SMA and fibronectin of cells and shows a remarkable anti-fibrosis effect. The small molecule compound Z1149421873 is used as an active ingredient for preparing the medicine with the myocardial fibrosis resisting effect, and the medicine is used for clinically treating myocardial fibrosis diseases and reversing the cardiac function of fibrosis damage and is applied to treating the myocardial fibrosis diseases.

A universal biological prosthesis of acellular dermal matrix (ADM) intended for use in body reconstruction processes and method of manufacture. A universal biological prosthesis of acellular dermal matrix (ADM) intended for use in body reconstruction processes, comprising: a first layer of ADM of biological origin arranged inferiorly to delimit a cavity with a lower edge; a filling material disposed in the cavity surrounded by the first layer of ADM consisting of a ground ADM having the consistency of a fibrous paste; and a second layer of ADM of biological origin arranged on the upper part covering the filling material and whose upper edge rests peripherally on the lower edge of the first layer of ADM, thus defining a rim;where the first layer of ADM and the second layer of ADM are joined by an eyebrow overlap along the upper edge of the first layer of ADM with the lower edge of the peripheral rim using a biocompatible adhesive, or by absorbable suture; where the first layer of ADM, the second layer of ADM and the ADM filling material are not immunogenic; and where the ADM comprises collagen fibers, fibronectin, elastin, laminin, glycosaminoglycans and hyaluronic acid. Method for its manufacture.